Skip to Main Content

Paper Details

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
J Clin Oncol
8
2022
70-gene signature, Breast Cancer, DRFI, Goserelin, Patients, Primary, Tamoxifen, breast cancer, cyclophosphamide, estrogen, estrogen receptor, fluorouracil, goserelin, methotrexate, patients, tamoxifen, tumor
Author NameAffiliation
Laura J Van't VeerUniversity of California San Francisco
Christina YauBuck Institute for Research on Aging
Christina YauUniversity of California San Francisco
Christina YauBuck Institute for Research on Aging
Christina YauUniversity of California San Francisco
Christopher C BenzBuck Institute for Research on Aging
Christopher C BenzUniversity of California San Francisco
Christopher C BenzBuck Institute for Research on Aging
Christopher C BenzUniversity of California San Francisco
  • 1 - 9

Datasets

Release 1.2